Related to Celgene Takes Option to Acquire VentiRx through TLR8 Agonist Deal

• Avastin Label Changes Reignites Debate: Is OS or PFS the Better Regulatory Endpoint?
  A recent panel discussion set the stage for defining standards for drug approval as separate from those for treatment decisions.
  
• 2011’s Five Biggest Biopharma Acquisitions Provide Clues for What’s Ahead
  Purchase of biotech giant Genzyme by Sanofi for $20.1 billion topped the list.
  
• This Year’s M&As Among Life Science Tool Firms Show Interest in Molecular Diagnostics
  Coming in at number one is Danaher’s purchase of diagnostic maker Beckman Coulter for $6.8 billion.
  
• M&A Activity Likely to Stay Hot in 2012 Though Blockbusters May Be Fewer
  Companies are looking down the road to padding their pipelines for long-term growth.
  
• How Provenge Laid the Groundwork for Developing and Regulating Cancer Vaccines
  FDA’s recently issued guidelines pull from more than 20 years of research and clinical experience.
  
• Immune Response Markers for Cancer Vaccines Paint a Clearer Picture
  In trying to understand what constitutes an effective immune response, researchers find it’s all about T cells.
  
• As Investors Eschew Risk, More M&A Deals Combine Cash with Milestone-Based Fees
  Buyers can hedge their bets, and sellers can ask for more contingent on pipeline assets.
  
• Buyout Options Gaining a Foothold in Deals Means that More than the Price Is Right
  Buyout rights are attractive to smaller firms as they offer up-front payments and a longer-term path to liquidity.
  
• M&A Likely to Continue Growing Along with Deal Premiums and Multiples
  Slow comeback of IPO market will keep companies looking for opportunities to be acquired.
  
• Leveraging the Cancer Transcriptome for New Drug Targets
  New analytical tools are advancing research efforts.
  
• Why Biomarker Discovery Is Hard
  Differentiating which markers are in the driver’s seat and which are along for the ride is key.
  
• Harvard Professor Rides Genomics' Third Wave
  New Firm Aims to Advance Personalized Medicine through Precision Diagnostics
  
• Will Less SOX2 Lead to Brain Cancer Getting Cold Feet?
  PLK1 level is elevated in glioblastoma multiforme, and its inhibition restricts the growth of brain cancer cells.
  
• Clinical Application of miRNAs Remains a Ways Off
  When and if its time comes, prognostic tests will likely be first.
  
• A SPA for PMTs
  Researchers propose a SPA strategy that can be successfully implemented to identify novel and specific inhibitors of PMTs.
  
• Leveraging Synthetic Lethality for Cancer Therapeutics
  Researchers investigate a class of therapeutics that could short-circuit cancer cells at the molecular level.
  
• Oncogene Addiction: Real or Not?
  Emerging documentation is starting to address that question and increase understanding of process.
  
• Fearing Anchors Away After M&A
  San Diego, Maryland downplay prospect of clusters’ last stand.
  
• End-Running Cancer Resistance to Targeted Therapies
  Overcoming resistance may require an assault on multiple fronts.
  
• A Cyber War on Cancer
  New strategies are hoping to put an end to the war that Richard Nixon declared four decades ago.